1-4 of 4
Ali Al Sbihi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Outcomes of IDH Mutant AML Patients Treated with or without IDH Inhibitors

Ali Al Sbihi, Sushmitha Nanja Reddy, Vikram Dhillon, Enxhi Lalo, Harry Ramos, Abdul Moiz Khan, Suresh Kumar Balasubramanian
Journal: Blood
Blood (2022) 140 (Supplement 1): 6189–6190.
https://doi.org/10.1182/blood-2022-171131
Published: 2022
Journal Articles

Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients

Sushmitha Nanja Reddy, Abdul Moiz Khan, Vikram Dhillon, Ali Al Sbihi, Amanda Tear, Breanna William, Sonubar Virk, Julie Boerner, Suresh Kumar Balasubramanian
Journal: Blood
Blood (2022) 140 (Supplement 1): 6584–6585.
https://doi.org/10.1182/blood-2022-170971
Published: 2022
Journal Articles

Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia

Abdul Moiz Khan, Sushmitha Nanja Reddy, Mai M M Aly, Vikram Dhillon, Ali Al Sbihi, Tariq Kewan, Waled Bahaj, Carmelo Gurnari, Bayan Al-Share, Gregory Dyson, Valeria Visconte, Suresh Kumar Balasubramanian
Journal: Blood
Blood (2022) 140 (Supplement 1): 1433–1434.
https://doi.org/10.1182/blood-2022-165696
Published: 2022
Journal Articles

Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia

Vikram Dhillon, Abdul Moiz Khan, Ali Al Sbihi, Sushmitha Nanja Reddy, Enxhi Lalo, Harry Ramos, Jay Yang, Anupama Kottam, Suresh Kumar Balasubramanian
Journal: Blood
Blood (2022) 140 (Supplement 1): 6183–6184.
https://doi.org/10.1182/blood-2022-169932
Published: 2022